drugset / Trial / NCT02027337
Hemocoagulation and Lipoperoxidation in Women Using Combined Oral Contraceptives, Correction by Antioxidants
RandomizedParallel-groupSingle-blindPrevention
Summary
We investigate parameters of hemocoagulation and lipoperoxidation in women using combined oral contraceptives with antiandrogenic activity (containing drospirenone with 20 or 30 mcg ethinylestradiol; or cyproterone acetate); correction of these changes by antioxidants
Timeline
- Start
- 2013-12
- Primary completion
- 2015-03
- Completion
- 2015-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Yasmin | Unknown | — | Oral |
| Subject | cyproterone acetate | Small molecule | 2 mg | Oral |
| Subject | drospirenone | Unknown | 3 mg | Oral |
| Subject | ethinyl estradiol | Small molecule | 20 ug | Oral |
| Subject | ethinyl estradiol | Small molecule | 30 ug | Oral |
| Subject | ethinyl estradiol | Small molecule | 35 ug | Oral |